A Serum Galectin-3 Levels in Placenta Accreta Spectrum Pregnancies

CompletedOBSERVATIONAL
Enrollment

60

Participants

Timeline

Start Date

December 1, 2021

Primary Completion Date

January 1, 2023

Study Completion Date

January 1, 2023

Conditions
Placenta Accreta, Third Trimester
Interventions
DIAGNOSTIC_TEST

Galectin 3

Women diagnosed with Placenta Accreta Spectrum (PAS) were invited to join the study, providing they had no known systemic diseases (e.g. chronic hypertension, diabetes, hypothyroidism, chronic renal-liver diseases, etc.), autoimmune disorders, multiple pregnancies, or the presence of fetal structural and chromosomal anomalies. They also did not have cholestasis of pregnancy, preterm delivery, or evidence of chronic and active infection.

Trial Locations (1)

Unknown

Necmettin Erbakan University Meram Medicine Faculty, Konya

All Listed Sponsors
lead

Necmettin Erbakan University

OTHER

NCT05945446 - A Serum Galectin-3 Levels in Placenta Accreta Spectrum Pregnancies | Biotech Hunter | Biotech Hunter